Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics presents a positive growth outlook, supported by management's guidance predicting significant revenue increases from Aucatzyl, with projections of $120M-135M for 2026, indicating a 60-80% year-over-year growth as the network expands. The substantial rise in CAR-T utilization in the UK, anticipated to be three times that of the US, is expected to further bolster the company's revenue potential by 2026. Additionally, the success of Blincyto in expanding its label and usage suggests a favorable market environment for Autolus’s programs, enhancing the appeal of its pipeline therapies.

Bears say

Autolus Therapeutics PLC has experienced a significant decline in its stock price, dropping approximately 48% since July 2025, in stark contrast to a 40% increase in the NASDAQ Biotechnology Index, which raises concerns about the company’s flat quarter-over-quarter revenue growth in B-ALL. The company's recent product Aucatzyl launched in the first quarter of 2025, but sales remained stagnant for the subsequent quarters, primarily due to limitations in manufacturing capacity and enrollment gaps that hindered product infusion readiness. Additional risks, including potential safety signals, insufficient efficacy in clinical trials, greater-than-expected competition, and financial concerns such as the anticipated need for $1.0 billion in capital through 2038, contribute to a negative outlook for Autolus Therapeutics's stock.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.